Full diagnostic status — code 6C72, Impulse-Control Disorders. Operative for clinical coding and epidemiological surveillance. Classification as an impulse-control disorder — rather than an addictive disorder — reflects a deliberate, evidence-based nosological choice by the WHO working group.
Absent from DSM-5-TR in any form — not in the main text, appendices, or among conditions requiring further study. The proposed Hypersexual Disorder construct was excluded from DSM-5 on grounds of insufficient research base; this determination has not been revised. No billing code is available in DSM-governed systems.
CSBD holds full diagnostic status within ICD-11 (6C72), classified within the Impulse-Control Disorders chapter. This placement was not incidental: the ICD-11 working group explicitly considered and rejected classification within the Addictive Behaviours block, concluding that available neurobiological evidence was insufficient to establish addiction-model primacy, and that the impulse-control framework — centering inhibitory failure and functional consequence rather than neurobiological dependence — better represented the operationally defensible construct. Clinicians should understand this distinction as substantive: the ICD-11 recognition does not confirm that CSBD is an addiction, and it should not be communicated as though it does.
DSM-5-TR’s exclusion is not merely administrative. It determines billing practice in DSM-aligned jurisdictions, shapes treatment access, and represents a different institutional assessment of the evidence threshold from the WHO’s. The practical implications for U.S.-based addiction psychiatrists are addressed in Section 8. The divergence between systems is currently unresolved; the responsible clinical posture acknowledges it explicitly rather than defaulting silently to either framework.
The criterion that separates clinically relevant disorder from intensive sexual engagement is functional impairment. Neither sexual frequency, behavioral content, high sexual desire, nor moral or religious distress about sexual behavior alone is sufficient for diagnosis. The operative diagnostic questions are whether the patient exhibits genuine loss of control over intense sexual impulses, and whether that loss of control produces material compromise in occupational, relational, health, or personal functioning. Prevalence inflation in the published literature is substantially attributable to studies that treat subjective distress — particularly moral incongruence — as a proxy for functional disorder; clinicians should be aware of this methodological problem when interpreting epidemiological figures.
ICD-11 specifies three core criteria, all of which must be present and must have caused clinically significant distress or functional impairment — not arising exclusively from moral or religious conflict with personal values — over a period of six months or more: (1) a persistent pattern of failure to control intense, repetitive sexual impulses or urges; (2) repetitive sexual behavior that has become a central organizing preoccupation displacing health, relationships, responsibilities, or personal care; and (3) continuation of sexual behavior despite repeated unsuccessful attempts to cease and despite adverse consequences across personal, relational, occupational, or health domains. Notably, ICD-11 explicitly does not require tolerance (escalation) or withdrawal phenomena as diagnostic features — their absence is not a criterion deficiency but a deliberate evidence-based judgment that many clinically impaired patients do not exhibit these addiction-model anchors.
The proposed Hypersexual Disorder criteria considered during DSM-5 development shared substantive overlap with the eventual ICD-11 formulation: both centered distress and functional impairment, both incorporated unsuccessful cessation attempts and persistence despite harm, and neither required tolerance or withdrawal as core features. The DSM-5 Working Group’s exclusion reflected methodological concerns about research base adequacy rather than conceptual incompatibility with the ICD-11 framing. This conceptual convergence is important context: the ICD-11 and DSM-5 working groups reached similar diagnostic architectures through different regulatory outcomes.
Moral Incongruence — The Critical Exclusion Criterion:
ICD-11 specifies that distress arising exclusively from conflict between sexual behavior and personal moral or religious values — in the absence of demonstrable functional impairment and genuine loss of control — does not constitute CSBD. A consistent body of research demonstrates that a meaningful proportion of individuals presenting with distress about sexual behavior, particularly pornography-related distress in religiously conservative populations, do not exhibit the behavioral dyscontrol and functional harm characteristic of the disorder. Their distress may be intense and their self-labeling confident; neither establishes the diagnosis. Failure to apply this exclusion criterion rigorously represents a clinically significant diagnostic error with potential for harm — including pathologizing a values conflict, reinforcing shame-laden self-narratives, and providing a clinical veneer to norm-compliance pressure. The structured clinical interview is the primary instrument for making this discrimination; no existing screening tool operationalizes it adequately.
Distress arising from perceived conflict between sexual behavior and personal moral or religious values, without demonstrable loss of control or functional impairment meeting ICD-11 criteria. Phenomenologically, the patient’s distress is genuine; subjectively, compulsion may be reported; self-labeling may be confident. None of these features establish CSBD in the absence of objective functional impairment and behavioral dyscontrol. Clinical interview must systematically probe whether reported distress is functionally mediated or primarily values-driven. Misdirecting values conflict into a behavioral disorder framework is a clinically significant error.
Hypomanic and manic phases can present with markedly elevated sexual drive and increased sexual behavior. ICD-11 explicitly excludes sexual behavior occurring solely within a manic or hypomanic episode. Differentiating features: episodic rather than persistent course; decreased sleep need without distress; elevated or expansive mood state; sexual behavior context-congruent with elevated energy rather than compulsive dyscontrol pattern; resolution of sexual behavior with mood stabilization. Longitudinal mood history is essential to exclude bipolar spectrum disorder before establishing a CSBD diagnosis.
Stimulant intoxication — amphetamines, cocaine, and related agents — has documented synergistic interactions with sexual behavior and can produce compulsive sexual behavior presentations during active use. Dopamine agonist therapy in Parkinson’s disease is a well-characterized pharmacological model of CSBD-relevant circuitry activation. Careful substance use history and timeline analysis are essential; some presentations substantially remit with substance use disorder treatment, while others require concurrent treatment of both conditions. The significant co-occurrence of CSBD and substance use disorders makes this differential particularly important in practice.
OCD presenting with intrusive, ego-dystonic sexual obsessions (often involving taboo or disturbing content) is phenomenologically distinct from CSBD. Key differentiating features: ego-dystonic quality of cognitions (obsessions are experienced as unwanted and repugnant rather than as urges); absence of behavioral enactment as a functional pleasure or dysphoric-affect regulatory mechanism; compulsive behaviors are neutralizing rituals (avoidance, reassurance-seeking, mental checking) rather than sexual acts; sexual obsession content is typically not the type of content the patient would seek out or desire. Misidentifying OCD as CSBD leads to therapeutically inappropriate treatment targeting.
Paraphilic disorders (sexual arousal patterns involving non-consenting persons, children, or other atypical stimuli causing harm or distress) can co-occur with CSBD and must be assessed independently. The presence of a paraphilic disorder does not establish CSBD; the presence of CSBD does not establish a paraphilic disorder. Co-occurring presentations require formulation of both conditions separately. CSBD comorbidity in paraphilic disorder samples shows particularly elevated ADHD rates (~50%) compared with normophilic hypersexuality samples (~17%), a differential with clinical management implications.
Depression-driven hyposexuality and social withdrawal are more common than hypersexual presentations, but MDD-associated anhedonia, loss of initiative, and behavioral changes may coexist with compulsive sexual behavior serving as an affect-regulation strategy. The bidirectional relationship is well-established: compulsive sexual behavior drives shame, secrecy, and functional decline that generates and maintains depressive states; depression drives compulsive sexual behavior as escape or dysphoric-affect regulation. Where both are present, both diagnoses are typically warranted and concurrent treatment is indicated.
CSBD rarely presents in clinical isolation. Psychiatric comorbidity is the rule rather than the exception in treatment-seeking populations, with a clustering pattern suggesting shared vulnerability factors and bidirectional maintenance relationships rather than simple co-occurrence. Mood disorders represent the most consistently documented comorbidity: some paraphilia-inclusive samples report lifetime rates of major depressive disorder or dysthymia exceeding 70%. The bidirectional relationship is well-characterized — depression drives compulsive sexual behavior as an escape or dysphoric-affect regulation strategy, while shame, consequences, and secrecy secondary to the disorder generate and maintain depressive states. Anxiety disorders, particularly social anxiety disorder, affect approximately 38% of clinical samples in some series, with social anxiety accounting for approximately 22%.
Substance use disorders co-occur at clinically significant rates: approximately 41% of some CSBD clinical samples report psychoactive substance abuse, with alcohol-specific rates approaching 30%. This co-occurrence is not merely statistical — it is mechanistically important. Unaddressed CSBD has been associated with elevated substance relapse risk, and the traditional sequential treatment approach (addressing substance use disorder first, then CSBD) is likely inadequate for patients in whom these disorders are mutually reinforcing. Integrated concurrent treatment is the more defensible clinical approach, and is detailed in Section 8.
ADHD comorbidity carries a particularly important clinical signal. Rates approximating 50% have been reported in paraphilic disorder samples, compared with approximately 17% in normophilic hypersexuality samples. The mechanistic hypothesis is that attentional dysregulation may directly contribute to the behavioral dyscontrol central to the ICD-11 construct — that inhibitory failure in CSBD may, in a substantial subpopulation, be mediated or amplified by underlying attentional pathology. The clinical implication is direct: ADHD assessment should occur early in the diagnostic workup, not as a late addition after primary treatment has failed. Initiating behavioral change protocols before ADHD is identified and treated may set patients up for predictable failure.
The construct of Addiction Interaction Disorder — the concept that multiple addictive behaviors in the same individual may operate as a mutually reinforcing syndrome — has practical clinical traction in this population. Large clinical series have reported that 69–80% of individuals with CSBD describe lifetime co-occurrence of other addictive or compulsive behaviors, with concurrent multi-addiction presentations documented in 40–60% of samples. Pathological gambling shows a particularly notable temporal relationship: CSBD appears to precede gambling disorder onset in the majority of co-occurring cases, suggesting CSBD may function as a primary disorder in the addictive cluster in some patients. Secure adult attachment style is markedly under-represented in clinical samples — available data suggest approximately 8% prevalence compared with approximately 40% in non-affected controls — and this attachment profile is likely part of the etiological and maintenance architecture of the disorder in many patients.
A comprehensive assessment requires systematic evaluation across functional impairment domains before and independently of any diagnostic determination. The structured clinical interview remains the most diagnostically reliable instrument, and no screening tool currently available substitutes for it. Relevant assessment domains include: whether patient distress reflects functional impairment and behavioral dyscontrol, or values conflict without functional consequence; the temporal relationship between sexual behavior and mood states; the nature and history of cessation attempts; functional consequences in identified life domains (relational, occupational, financial, health); attachment patterns and relational history; substance use history and current status; mood and anxiety symptom burden; ADHD-consistent symptom history; trauma history; and the patient’s self-framing of their presentation, which may reflect internet-derived or peer-group-derived narratives requiring careful examination rather than automatic validation. Comorbidity assessment is not an optional adjunct — it is a prerequisite for adequate treatment planning.
Validated Screening Instruments — Critical Limitations:
The PATHOS questionnaire and the Sexual Addiction Screening Test-Revised (SAST-R) are the most widely used formal screening instruments. PATHOS captures preoccupation, shame and concealment, treatment history, harm to others, perceived loss of control, and post-coital dysphoria. SAST-R evaluates sexual preoccupation, loss of control despite consequences, relational disturbance, and affect disturbance. Both have clinical utility as structured prompts ensuring systematic symptom coverage.
Critical limitation: All major CSBD screening instruments were developed and validated within an addiction-model conceptual framework and have not been re-validated against ICD-11 impulse-control criteria. More significantly, no widely used instrument adequately operationalizes the moral incongruence exclusion criterion — the most diagnostically consequential distinction in CSBD assessment. Positive screening results constitute clinical prompts requiring confirmatory interview, not diagnostic findings. Instrument selection should be accompanied by explicit acknowledgment of these limitations, and results should never be communicated to patients as diagnostic in themselves.
Red flags warranting prioritized assessment include: documented functional impairment across multiple life domains with clear temporal relationship to sexual behavior; significant relational disruption or partner-reported harm; evidence of sexual behavior in high-risk contexts involving legal, financial, or health consequences; co-occurring substance use disorder; and clinical features consistent with ADHD, bipolar spectrum disorder, or trauma history. In presentations where the patient’s self-report is heavily shaped by internet-derived addiction-model framing, clinical rigor in applying the ICD-11 criteria — rather than accepting the patient’s framing — is essential to avoid the well-documented overdiagnosis problem. Retrospective chart review data suggest that as few as approximately one in four patients presenting with a presumptive self-label of sexual addiction meet formal diagnostic criteria on structured clinical assessment.
No single evidence-based treatment protocol has been established for CSBD. This is an accurate statement of the current science, not a provisional hedge. The multimodal biopsychosocial treatment approach that constitutes current standard practice adapts frameworks developed primarily for substance use disorders, sexual offending, and OCD, rather than representing a validated CSBD-specific treatment architecture. The absence of DSM recognition has historically impeded development and funding of rigorous CSBD-specific clinical trials, creating a circular problem: insufficient evidence base contributed to DSM exclusion, and DSM exclusion has impeded the research that would generate the evidence base.
Cognitive-Behavioral Therapy (CBT) is the most extensively described psychological intervention, adapted from substance use disorder, sexual offending, and OCD frameworks. Core CBT components include: trigger identification and functional analysis of behavioral antecedents; cognitive restructuring targeting permissive cognitions, minimization, and rationalization; behavioral intervention including stimulus control and planned behavioral substitution; and relapse prevention planning anchored in high-risk situation identification and lapse management. Available small-scale studies demonstrate clinical benefit. The evidence does not support statements of established efficacy for CSBD-specific CBT protocols; CBT should be represented as the most systematically described and logically grounded first-line psychological intervention rather than as empirically validated to the standard applicable to CBT in panic disorder or social phobia.
Dialectical Behavior Therapy (DBT) has gained increasing clinical application, driven by recognition that compulsive sexual behavior frequently functions as a primary dysphoric mood-regulation strategy. The core DBT target in CSBD treatment is affect regulation — building the patient’s repertoire of effective emotional regulatory strategies sufficient to reduce reliance on sexual behavior as the primary coping mechanism. DBT’s modules in distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness address the psychological terrain that maintains compulsive sexual behavior in patients with prominent affect dysregulation. The evidence base for DBT in CSBD specifically is limited to clinical observation and extrapolation from DBT’s established efficacy in affect dysregulation and impulsive behavior disorders more broadly. Motivational Interviewing (MI) is a relevant engagement and ambivalence-resolution framework, particularly at treatment entry and during periods of relapse, and functions as a complement to rather than substitute for skills-based intervention.
Pharmacological treatment lacks an established, validated evidence base. No agent is approved specifically for CSBD by any regulatory authority. Naltrexone and nalmefene carry the most logically coherent mechanistic rationale: opioid antagonism is hypothesized to reduce the rewarding and craving-associated aspects of compulsive sexual behavior by blocking mu-opioid receptor activation within mesolimbic reward circuitry, directly analogous to naltrexone’s established mechanism in alcohol use disorder and gambling disorder. Case series and limited controlled data report reductions in sexual preoccupation and behavioral frequency at doses of 50–150 mg daily; the evidence is encouraging but insufficient to establish naltrexone as a first-line pharmacotherapy by established-evidence standards. SSRIs have been evaluated on the basis of OCD-spectrum mechanistic reasoning, with limited controlled evidence and inconsistent response; potential clinical utility in presentations with prominent compulsive phenomenology, OCD-spectrum features, or co-occurring depressive and anxiety disorders. Anti-androgen and hormonal agents are predominantly indicated in forensic or mandated treatment contexts involving paraphilic disorders or significant risk to others; their use in voluntary outpatient non-forensic CSBD is generally not indicated as first-line treatment given side-effect profile and ethical dimensions of drive suppression.
Evidence Limitations: CSBD-specific treatment trials are characterized by small sample sizes, heterogeneous populations, absence of validated ICD-11-anchored outcome measures, and methodological inconsistency. Unlike Gaming Disorder, where controlled trials exist — even if geographically constrained — CSBD pharmacotherapy evidence is largely limited to open-label data and case series. Psychotherapy evidence is extrapolated from adjacent fields. No adequately powered, methodologically rigorous RCT has been completed for any modality specifically in a well-characterized CSBD population using ICD-11 criteria. Cross-population and cross-cultural generalizability of available data cannot be assumed. Treatment claims should be calibrated to this evidentiary status in clinical teaching and patient-facing communication.
[Nosological Classification] The addiction-versus-impulse-control debate is the most fundamental unresolved question in CSBD scholarship, and it was not settled by ICD-11 recognition — the WHO working group explicitly preserved it as an open research question by classifying CSBD in the impulse-control chapter. The debate has direct clinical implications: if CSBD is primarily an addiction, dopaminergic targets and reward-sensitization reversal are the most rational pharmacological axes; if it is primarily an impulse-control disorder, frontal-lobe inhibitory circuitry and cognitive-regulatory interventions are the primary biological targets. In practice, the treatment approaches for either framing converge substantially — which is perhaps why the clinical urgency of the debate has been overstated relative to its scientific importance. Resolution requires multi-modal neurobiological research with standardized ICD-11-anchored criteria, adequate samples, and longitudinal designs capable of distinguishing cause from consequence.
[Overdiagnosis and Pathologization Risk] The most consequential diagnostic challenge is the well-documented risk of pathologizing moral incongruence as behavioral disorder. A consistent research literature demonstrates that subjective distress about sexual behavior — including the phenomenology of compulsion, the intensity of shame, and the confidence of self-labeling — does not reliably track functional impairment in the clinical sense. Studies of pornography-related distress, particularly in religiously conservative populations, have demonstrated that self-reported addiction rates substantially exceed defensible clinical prevalence. Retrospective chart review data suggesting that approximately 25% of self-labeled sexual addicts meet formal criteria on structured assessment quantify this overdiagnosis risk concretely. The ICD-11 exclusion criterion for moral incongruence exists precisely to address this problem and should be applied rigorously, not treated as a bureaucratic qualification. Pathologizing a values conflict carries direct potential for harm.
[Neurobiological Evidence Status] The behavioral addiction model draws on structural and functional analogy with Substance Use Disorder. Available human neuroimaging data are scientifically interesting but do not yet establish either addiction-model or impulse-control-model primacy. Reward-circuit activation patterns in cue-reactivity paradigms overlap with addiction-relevant regions, and frontal cortex modulation of arousal states has been identified — but studies are characterized by small samples, heterogeneous populations, cross-sectional designs, and the absence of pre-registered hypotheses. Causal inference is not supportable from the current literature. The field has not produced neurobiological biomarkers for CSBD that inform diagnosis or treatment selection; communicating existing neuroimaging findings as though they have done so is not defensible. Parkinson’s disease dopamine agonist-induced compulsive sexual behavior provides one of the methodologically cleaner naturalistic models for dopaminergic modulation of CSBD-relevant circuitry and may have broader mechanistic relevance.
[Gender, Cultural, and Population Validity Gaps] The research base is predominantly derived from male, heterosexual, and Western populations. Female behavioral phenotypes appear qualitatively distinct from male presentations — characterized more commonly by fantasy-based engagement, relational sexual use, and seductive role behaviors, rather than the voyeurism, anonymous contact, and exploitative patterns more common in male samples. LGBTQ+ presentations may involve additional moral incongruence dynamics related to sexual identity that complicate the exclusion criterion assessment. Non-Western populations are substantially underrepresented across all levels of the evidence base — diagnostic norms, prevalence estimates, comorbidity profiles, and treatment data. No validated cross-cultural adaptation of CSBD assessment instruments exists for most non-represented regions. Clinical application of CSBD criteria across diverse populations should be accompanied by explicit epistemic humility.
The most immediately actionable research priority in CSBD assessment is the re-validation of existing screening instruments against ICD-11 functional impairment criteria, and the development of instruments capable of reliably distinguishing functional CSBD from moral incongruence presentations. This is a prerequisite for valid prevalence research, treatment outcome measurement, and clinical gatekeeping — not a minor methodological refinement. Until instruments operationalizing the moral incongruence exclusion criterion are developed and validated, prevalence estimates derived from existing instruments should be treated with appropriate skepticism. The PATHOS and SAST-R were both developed within addiction-model frameworks and have not been re-validated against ICD-11 impulse-control criteria; their psychometric properties in morally incongruent populations are inadequately characterized.
Longitudinal data represent the most significant methodological gap across the field. The majority of neurobiological, epidemiological, and clinical studies are cross-sectional, preventing determination of whether structural and functional findings represent predisposing vulnerabilities, neuroplastic consequences, or bidirectional relationships. Causal directionality is unresolved for most documented comorbidities. The treatment evidence base requires dedicated investigation: priority domains include randomized controlled trials of naltrexone in well-characterized ICD-11-defined CSBD populations; trials of CBT protocols specifically developed and manualized for CSBD rather than adapted from adjacent fields without CSBD-specific validation; and investigation of DBT’s efficacy in populations with prominent affect dysregulation. Development of validated, ICD-11-anchored outcome measures is a prerequisite for this research agenda. The DSM inclusion question — whether future revisions will incorporate CSBD — will turn on whether the field generates the kinds of well-characterized epidemiological data, validated diagnostic instruments, and treatment response evidence that the DSM-5 Working Group found insufficient in 2013. The ICD-11 criteria now provide the diagnostic anchor for that research agenda.